| Novartis confirms that it has received a report of a PML (progressive multifocal leukoencephalopathy) case. The patient had been receiving Gilenya (fingolimod) for the treatment of relapsing MS (RMS) for more than 4 years. The diagnosis was made based on MRI findings and additional tests for JC (John Cunningham) virus. The patient is currently doing well. The case has been reported to Health Authorities. The positive benefit-risk profile of Gilenya in relapsing MS is based on experience with 114,000 patients treated with Gilenya and more than 195,000 patient years and accumulation of real-world efficacy and safety data. |
Novartis Global Investor Relations / General phone: +41 61 324 79 44
Samir Shah / Global Head Investor Relations +41 61 324 79 44
| Basel Office | North America Office | ||
| Pierre-Michel Bringer Thomas Hungerbuehler Isabella Zinck | +41 61 324 10 65 +41 61 324 84 25 +41 61 324 71 88 | Richard Pulik Susan Donofrio | +1 212 830 24 48 +1 862 778 92 57 |
e-mail: investor.relations@novartis.com | www.novartis.com